Taken together, these results suggested that SIRPG plays a significant role in T cell mediated-adaptive antitumor immunity and would be a promising predictive biomarker for PD-1 blockade in cancers and a novel immunotherapeutic target. This evidence concerns the gene PDCD1 and cancer.